Topokine Therapeutics, a Newton, MA-based clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, received a financing from Schooner Capital.
The amount of the transaction was not disclosed.
Led by Murat Kalayoglu, MD, PhD, President and CEO, Topokine Therapeutics is advancing XAF5 Gel, a skin cream being developed for local reduction of excess subcutaneous fat.
The company intends to use the proceeds to develop its pipeline, including XAF5 Gel, which is now in a Phase I Clinical Trial whose results are expected in the first half of 2013.
FinSMEs
22/01/2013